Ensysce Biosciences Inc (NASDAQ: ENSC)’s stock price has increased by 90.91 compared to its previous closing price of 1.87. However, the company has seen a 59.38% increase in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-23 that ~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof¹ including both composition of matter and method of use claims. PF9001, the innovative medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysce’s TAAPTM and MPAR® abuse deterrent and overdose protection technologies.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
Additionally, the 36-month beta value for ENSC is 1.20. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENSC is 1.62M and currently, short sellers hold a 1.94% ratio of that float. The average trading volume of ENSC on April 23, 2025 was 75.73K shares.
ENSC’s Market Performance
ENSC stock saw a decrease of 59.38% in the past week, with a monthly decline of -0.83% and a quarterly a decrease of -56.88%. The volatility ratio for the week is 14.85%, and the volatility levels for the last 30 days are 14.52% for Ensysce Biosciences Inc (ENSC). The simple moving average for the last 20 days is 53.80% for ENSC stock, with a simple moving average of -39.63% for the last 200 days.
ENSC Trading at -7.04% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.66% of loss for the given period.
Volatility was left at 14.52%, however, over the last 30 days, the volatility rate increased by 14.85%, as shares surge +5.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.38% lower at present.
During the last 5 trading sessions, ENSC rose by +64.73%, which changed the moving average for the period of 200-days by -46.52% in comparison to the 20-day moving average, which settled at $2.3275. In addition, Ensysce Biosciences Inc saw -56.14% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -13.8 for the present operating margin
- -0.94 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -16.38. The total capital return value is set at -1.99. Equity return is now at value -471.82, with -192.33 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -24.87. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -5.22.
Currently, EBITDA for the company is -6.73 trillion with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of 19.16. The receivables turnover for the company is 3.93for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.42.
Conclusion
In conclusion, Ensysce Biosciences Inc (ENSC) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
